We've turned drug discovery into a search query
Natural products are the greatest untapped opportunity for drug discovery. We have built the tools to capture it.
Our PlatformLearn more
New Medicines
Nature’s chemistry has evolved under billions of years of selective pressure to modulate life’s fundamental phenomena. This has led to incredible diversity of chemical properties and biological activity. This diversity is uncharacteristic of historical small molecule libraries and inaccessible to even cutting-edge library generation technologies. We’re harnessing this ancient cache to rapidly discover and deliver new medicines, and hope, to patients suffering a range of complex diseases.
New Modalities
Our chemistry provides a unique opportunity to access known and emerging mechanisms of tuning biological activity of proteins. We are rapidly identifying novel chemistries that provide new and useful mechanisms for manipulating disease-relevant proteins. These include chemistries that can degrade or stabilize proteins, that can change the shape of difficult-to-drug proteins thus allowing modulation of target, or that can covalently inhibit specific proteins.
New Targets
Uncovering how nature’s diverse chemistry manipulates human biology is a powerful way to understand the basis of disease. Just as the study of rapamycin once led to the discovery of mTOR signaling, we have built technologies that rapidly uncover novel disease targets while simultaneously advancing these molecules as new medicines. Get in touch to learn more!
Partner with us
Our Pipeline
Moa
Therapeutic area
Discovery
Optimization
Ind-enabling
Clinical
Undisclosed
Pain
Multi-Modal
Dermatology
Neutrophil Modulator
Immunology & Inflammation
NLRP3 Pathway
Immunology & Inflammation
Immunology & Inflammation
TGR5
Immunology & Inflammation
Undisclosed (15+)
Undisclosed
mixture
hits
%20-%20Copia.avif)
Lead
Identification
Desease
Validation
Lead
Optimization
Liver InflaMmation
2 Chemical Series
Neuroinflammation
5 Chemical Series
NF-kB / IL-1B signaling
29 Chemical series
NLRP3 inflammasome
1 Chemical series
Gut-restricted
fxr agonism
.svg)
1 Chemical series
Gut-restricted
tgr5 agonism
1 Chemical series
Nav 1.7
1 Chemical series
PCSK 9
6 Chemical series
Ind-
enabling
Indication
Nash, Wilson's disease
Parkinson’s disease, als
Acute liver failure, multiple
Multiple
NASH, PBC, IBD
Type ii diabetes
Pain
Hypercholestrolemia
Our Pipeline
TARGET/Moa
Therapeutic area
Discovery
Optimization
Ind-enabling
Clinical
Neutrophil Activation
Inflammation & Fibrosis
NLRP3
Inflammation & Fibrosis
Inflammation & Fibrosis
Ion-Channel Inhibitor
Pain
Dermatology
Undisclosed
Dermatology
TGFβR1 (ALK5)
Inhibitors
Dermatology
Fibrosis
TGR5
Inflammation
Cytokine Signaling
Inhibitors
Multiple
mixture
hits
Lead
Identification
Desease
Validation
Lead
Optimization
Liver InflaMmation
2 Chemical Series
Neuroinflammation
5 Chemical Series
NF-kB / IL-1B signaling
29 Chemical series
NLRP3 inflammasome
1 Chemical series
Gut-restricted
fxr agonism
1 Chemical series
Gut-restricted
tgr5 agonism
1 Chemical series
Nav 1.7
1 Chemical series
PCSK 9
6 Chemical series
Ind-
enabling
Indication
Nash, Wilson's disease
Parkinson’s disease, als
Acute liver failure, multiple
Multiple
NASH, PBC, IBD
Type ii diabetes
Pain
Hypercholestrolemia
New Targets
Uncovering the biological basis of the effects of nature’s diverse chemistry is a powerful way to understand the basis of disease itself. Just as the the study of Rapamycin once led to the discovery of mTOR signaling, we have built technologies that rapidly uncover novel disease targets. Get in touch to learn more!
Our Advantages
Biologically Relevant Library
Shaped by evolution
Unique Technology Platform
Overcomes the historical challenges of bioactivity annotation, structure elucidation, and manufacturing
>10x greater hit rates
In a head-to-head comparison with synthetic libraries across difficult targets
Prolific source of next-generation compounds
Molecular glues and protein-protein interaction disruptors
Discovery compatible across screening platforms
Target-binding, target-activity, or phenotypic screening
Quick links
Locations
